Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Popat S, Tanna N, Hartridge-Lambert S, Kiff C, Sowdani A, Rothwell B, Brodtkorb T-H, Ling C, Smittenaar R, Bomb M, Turnbull A. Nivolumab in second line non-small cell lung cancer – comparing real-world outcomes in England to CheckMate (CM) 017 and 057. Poster presented at the IASLC 2020 Virtual World Conference on Lung Cancer; January 28, 2021.
Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis. Curr Med Res Opin. 2017 Aug;33(8):1457-66. doi: 10.1080/03007995.2017.1325730
Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA. Efficacy of palbociclib combinations versus endocrine therapies in advanced/ metastatic breast cancer: network meta-analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A710.
Boysen M, Tyas D, Ling C, Wolowacz S. The new NICE cancer drugs fund technology appraisal process: your questions answered. Presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria.
Ling CS, Weisgerber-Kriegl U, Njue AI, Heyes A, Kaye J. The effect of positive margins on outcomes in breast cancer. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A394.